Agenda
Applications for consideration at this meeting
- 1196.3 Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression (resubmission)
- 1353.1 Measurement of Calprotectin as a marker of bowel inflammation
- 1408 A prognostic RT-qPCR test run locally for ER+ve /HER2-ve breast cancer that determines the risk of early and late metastasis in node negative and positive cancer under endocrine treatment.
- 1492 Non-invasive prenatal testing (NIPT)
- 1512 Apolipoprotein B testing for high risk cardiovascular disease risk assessment
- 1519.1 Tisagenlecleucel (CTL019) for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 1523 Transluminal insertion, management, repositioning and removal of an intravascular microaxial blood pump (Impella®), for patients requiring mechanical circulatory support
- 1528 Somatic tumour gene testing for the diagnosis of renal cell carcinoma, hydatidiform moles, granulosa cell ovarian tumour, salivary gland tumours, and secretory carcinoma of the breast
- 1533 Genome-wide microarray testing for pregnancies with major foetal structual abnormalities detected by ultrasound
- 1542 Endovascular insertion of flow diversion device (FDD) for the treatment of unruptured intracranial aneurysms (UIAs)
- 1544 Genome-wide microarray testing for people with multiple myeloma and chronic lymphocytic leukaemia
- 1546 Abdominoplasty with repair of rectus diastasis (aka rectus divarication) following pregnancy
- 1554 Testing of tumour tissue or blood to detect somatic or germline BRCA1 or BRCA2 gene mutations, in a patient with newly diagnosed, advanced (FIGO stage III-IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to first-line platinum-based chemotherapy)
- 1555 Endoscopic Sleeve Gastroplasty (ESG) for the treatment of patients with Class I and Class II obesity with comorbidities who have failed first-line treatments
- 1560 17p Deletion Testing by FISH for Access to Ibrutinib in Patients with Previously Untreated Chronic Lymphoid Leukaemia or Small Lymphocytic Lymphoma
- 1562 Streamlining Medicare Benefits Schedule Items for Positron Emission Tomography (PET) Project
- 1565 Review of immumnoglobulin use for acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation
- 1587 YESCARTA™ (axicabtagene ciloleucel [KTE-C19]) for the treatment of refractory or relapsed CD19-positive lymphoma
- 1606 Request to amend existing MBS Item No 73341 (Fluorescence in situ hybridisation test of tumour tissue from a patient with locally advanced or metastatic non-small cell lung cancer) to add brigatinib
- 1626 Mentor Textured breast implants and expanders compared with smooth breast implants and expanders on the Prostheses List
Related information
Committee: